LONDON, December 10, 2012 /PRNewswire/ --
A new report by visiongain predicts that the world market for drug discovery outsourcing will reach $16.6bn in 2015. That revenue forecast and others appear in Drug Discovery Outsourcing: World Market 2013-2023, published in November 2012. Visiongain is a business information provider based in London, UK.
Visiongain forecasts that the drug discovery outsourcing market will experience high revenue growth from 2013 to 2023. Expansion of the market will be stimulated by the rising costs of pharma research and development (R&D), advancing technologies and development of biologics (biological drugs). The complexity and technological advances in drug discovery will make it more challenging for many companies to conduct drug discovery in-house. Visiongain predicts that more companies will use contract service providers to gain access to technologies and skills not available in-company. Outsourcing has the advantage of flexibility, whereby a company does not have to invest heavily in facilities and equipment for research.
Opportunities in drug discovery include the formation of strategic alliances between pharmaceutical companies and contract research organisations (CROs) - a trend that will increase. In addition, niche CROs are well placed to provide services for companies needing specialised pharma research. In 2012, the drug discovery services industry is fragmented; that situation is unlikely to change soon. Service providers will still compete in crucial areas of price, quality and range of services, the study shows.
Dr Peter Williamson, a pharmaceutical industry analyst in visiongain, said: "Drug discovery outsourcing is the reaction and solution to a changing pharma R&D climate. The global healthcare market will continue to have many unmet needs, requiring novel drugs to treat diseases. For example, targeted therapies in areas such as oncology and CNS disorders have high developmental needs. Outsourcing offers a platform for companies to reduce costs and improve their drug development, including getting faster and more-dependable results. There are also cost savings possible.
"Outsourcing drug discovery will result in strong revenue growth for those services in emerging countries such as China and India. Developed countries will also achieve high growth, especially to 2017, our findings show. However, entry into emerging national markets will involve challenges. For example, harmonisation of regulatory and intellectual property (IP) rights must be addressed to maintain confidence in developing countries' markets. Quality is paramount. The US and European early-stage drug development markets will also remain competitive, offering logistical advantages and well developed technologies, including biomarkers, genomics and proteomics."
Visiongain's report gives revenue forecasts to 2023 at overall world market, service submarket and national level. It forecasts world sales for the following segments:
• Chemical services
• Biological services
• Lead optimisation
• Lead identification and screening.
That investigation includes analyses of 13 leading companies, including Quintiles, Charles River Laboratories, Aptuit, Evotec, GenScript, PPD, WuXi AppTec and Albany Molecular Research.
The study includes researching trends and forecasting revenues in leading national markets. Countries analysed are the US, Japan, Germany, France, the UK, Spain, Italy (EU5), Brazil, Russia, India and China (BRIC nations). The analysis also discusses opportunities and developments - technological and commercial.
Drug Discovery Outsourcing: World Market 2013-2023 adds to visiongain's range of analytical reports on industries and markets in healthcare, including those on pharmaceutical outsourcing.
For sample pages and further information concerning the Visiongain report Drug Discovery Outsourcing: World Market 2013-2023 please visit http://www.visiongain.com/Report/945/Drug-Discovery-Outsourcing-World-Market-2013-2023
Advion Bioanalytical Labs
Albany Molecular Research, Inc (AMRI)
American Cancer Society
Associação Brasileira de CROs (Abracro)
Beijing Genomics Institute
Bundesverband Medizinischer Auftragsinstitute (BVMA)
Catalent Pharma Solutions
Charles River Laboratories
Discovery Partners International
Dow Chemical Company
Evotec BioSystems AG
Fidelity Growth Partners India (FGPI)
Food and Drug Administration (US FDA)
Great Lakes Chemical Corporation
Harvard Medical School
Hellman & Friedman
Johnson & Johnson (J&J)
Janssen Pharmaceutical Group
Massachusetts General Hospital
Merck & Co.
National Institutes of Health (NIH)
Oxford Asymmetry International
Peking Union Lawke Biomedical Development
Pharmaceutical Product Development (PPD)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Piedmont Research Center
Proteros Biostructutres GmbH (Proteros)
Rules-Based Medicine (RBM)
Southwestern Medical Center
Swiss Pharma Contract
SYN|thesis Med Chem
The Dow Chemical Company
The European CRO Federation (EUCROF)
The Institute of Cancer Research
The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
The Organization for Economic Cooperation and Development (OECD)
University of Manchester
WIL Research Laboratories
World Health Information Science Consultants (WHISCON)
World Health Organization (WHO)
World Trade Organization (WTO)
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44-(0)20-7336-6100
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Aviation, Automotive and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material.
For an executive summary please contact:
Email: Sara Peerun on email@example.com